Skip to main content
Assets
Doximity logo
DOCS.NYSE
Doximity
Health Care · Health Care Technology

Doximity, Inc. operates as a digital platform for medical professionals in the United States.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Doximity.

Historical AI Opinions

Doximity Inc (DOCS.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated
Ray Dalio AI advisor icon
Gemini 3 Pro

Ray Dalio AI

The Strategist Framework

Model rating

Strong Buy

5-Year Return Est.

+247.2%

DOCS.NYSE does not currently pay dividends

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.11.4235.2959.1583.02106.89Jun 2021Dec 2023May 2026Nov 2028May 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$25.0+0.0%

What dominates the short term? The macro energy shock and Warsh yield steepening. Capital is hiding in hard assets, not healthcare tech. The Q1 earnings will likely reflect the ongoing TrumpRx pharma freeze, keeping top-line growth weak. However, the 500 million dollar buyback acts as a hard floor.

  • Frictions: Macro energy squeeze and Warsh multiple compression dominate.
  • Drivers: Share buybacks prevent further downside.
  • Net result: A choppy, flat period as the stock stabilizes at cycle lows.
$27.0+8.0%

Is the cycle turning? The initial panic from the Q4 guidance miss fades. Institutional value hunters notice the 55 percent EBITDA margins and zero debt.

  • Drivers: The buyback program aggressively retires float, creating mechanical EPS growth.
  • Drivers: Early Q2 earnings show stabilization in user engagement.
  • Frictions: Ad budgets remain tight, but the worst is priced in.
  • Net result: The stock breaks out of capitulation and begins its early discovery phase upward.
$30.2+21.0%

How do we fix growth? Monetization. By late 2026, the AI Scribe tool transitions from free beta to paid enterprise contracts.

  • Drivers: AI Workflow Monetization begins showing up in the Annual Recurring Revenue.
  • Drivers: The new calendar year brings refreshed pharma marketing budgets.
  • Frictions: AI compute costs slightly drag on gross margins.
  • Net result: The alpha gap begins closing rapidly as Wall Street realizes the structural software transition is working.
$33.2+33.1%

The machine is accelerating. As the regulatory shock of TrumpRx is fully digested, pharma companies realize they still need to sell drugs.

  • Drivers: Pharma Budget Thaw kicks in, driving a cyclical rebound in the core ad business.
  • Drivers: Monopoly network effects ensure ad dollars flow directly to DOCS.
  • Frictions: Big Tech EHR competition narrative creates some headline noise.
  • Net result: Double-digit percentage gains as both ad revenue and SaaS revenue compound simultaneously.
$36.6+46.4%

We are moving from stabilization to momentum. The market starts pricing DOCS not as a broken ad network, but as an essential healthcare AI utility.

  • Drivers: Extreme gross margins generate massive free cash flow, which is immediately used for more buybacks.
  • Frictions: The broader macro environment remains structurally tight, limiting extreme multiple expansion.
  • Net result: Strong continued price appreciation driven entirely by fundamental earnings power.
$39.5+58.1%

What happens when you survive a bear market with no debt? You become a safe haven.

  • Drivers: Pristine balance sheet attracts institutional capital fleeing highly leveraged tech.
  • Drivers: AI workflow adoption crosses 500,000 active prescribers.
  • Frictions: Customer concentration risk causes slight volatility around contract renewals.
  • Net result: Steady compounding growth as the stock consolidates its recent gains and pushes higher.
$42.6+70.7%

Seasonality meets structural growth. The fiscal Q3 period traditionally features heavy pharma marketing spend to exhaust year-end budgets.

  • Drivers: Pharma budget normalization drives strong top-line beats.
  • Drivers: The share float is now significantly reduced due to two years of aggressive buybacks.
  • Frictions: Rising customer acquisition costs for new health system contracts.
  • Net result: Another solid leg up as earnings mechanically beat consensus estimates.
$45.6+82.7%

The economic machine enters a mid-cycle expansion phase.

  • Drivers: The AI Scribe product is fully mature and deeply embedded in physician daily habits, cementing the network effect.
  • Frictions: The AI capex tax stabilizes but remains a permanent feature of the cost structure.
  • Net result: Mid-single digit gains as the stock transitions from a deep-value recovery play into a reliable growth compounder.
$48.8+95.5%

Cash flow is king. Doximity's structural profitability shines in the Q1 fiscal reports.

  • Drivers: Operating leverage kicks in as revenue growth outpaces fixed cost expansion.
  • Drivers: Continued pristine capital allocation by management.
  • Frictions: Valuation multiples approach historical norms, requiring earnings to do the heavy lifting.
  • Net result: Consistent upward price action supported by unassailable free cash flow generation.
$51.8+107.2%

The moat is validated. Competitors have tried and failed to break the 80 percent physician monopoly.

  • Drivers: Network effects prove insurmountable for new entrants.
  • Drivers: Pharma clients expand their wallet share on the platform as targeted digital ROI outperforms legacy marketing.
  • Frictions: General market fatigue after a prolonged bull run.
  • Net result: Steady, low-volatility appreciation as DOCS acts as a bedrock portfolio asset.
$54.9+119.6%

A predictable machine. Q3 earnings confirm the enterprise SaaS transition is complete.

  • Drivers: Recurring software revenue now matches or exceeds cyclical advertising revenue, drastically improving earnings quality.
  • Frictions: The sheer size of the company makes hyper-growth percentages mathematically difficult.
  • Net result: Solid compound growth as the variant perception is now the fully accepted consensus.
$58.2+132.8%

Deflation in the cost of compute provides a margin tailwind.

  • Drivers: As foundational AI models become cheaper, the AI capex tax drops, leading to gross margin expansion back toward the low 90s.
  • Drivers: High free cash flow funds potential strategic M&A to expand the product suite.
  • Frictions: Integration risks if acquisitions are pursued.
  • Net result: Continued price appreciation driven by operational efficiency gains.
$61.6+146.8%

Expanding the borders of the walled garden.

  • Drivers: Doximity begins successfully penetrating allied health professionals (nurse practitioners, PAs) or exploring international English-speaking markets.
  • Frictions: Regulatory hurdles in new jurisdictions or professions.
  • Net result: The Total Addressable Market expands, justifying continued positive price action and renewing growth narratives.
$64.7+159.1%

The enterprise flywheel is spinning.

  • Drivers: Health systems are fully locked into DOCS workflow tools for telehealth and secure communication. Switching costs are astronomical.
  • Drivers: The pristine balance sheet remains bulletproof.
  • Frictions: Saturation of the core US physician market limits domestic user growth.
  • Net result: Stable, moderate gains as the company extracts maximum value per user.
$68.0+172.0%

Approaching late-cycle dynamics in the broader economy.

  • Drivers: Doximity's high margins and essential healthcare utility make it a defensive powerhouse.
  • Frictions: Macroeconomic slowing limits hospital system IT budgets.
  • Net result: DOCS outperforms the broader market due to its all-weather characteristics, delivering positive but moderate returns.
$71.4+185.6%

The terminal valuation phase.

  • Drivers: Massive accumulated cash hoard may lead to the initiation of a regular dividend or a massive special dividend.
  • Frictions: Ad revenue growth flattens completely as the market is fully penetrated.
  • Net result: Steady equity compounding supported by aggressive capital return policies.
$74.9+199.9%

Reaping the rewards of a decade of dominance.

  • Drivers: The physician network is intergenerational, with medical students onboarding immediately and staying for their entire careers.
  • Frictions: None significant beyond general market beta.
  • Net result: Reliable, low-volatility price appreciation mirroring the growth of the broader healthcare sector.
$79.4+217.9%

End-of-cycle defensiveness pushes institutional capital into high-margin staples.

  • Drivers: Healthcare technology is treated as a non-discretionary utility. DOCS's zero debt profile makes it a safe haven against sovereign debt volatility.
  • Frictions: Extreme valuations in the safe-haven sector limit upside bursts.
  • Net result: Strong relative outperformance as the economic machine shifts toward a protective stance.
$82.6+230.6%

Q3 seasonal peak.

  • Drivers: Pharma marketing spend remains highly efficient on the platform. AI tools are fully autonomous, driving maximum physician engagement.
  • Frictions: The law of large numbers constrains percentage growth rates.
  • Net result: Moderate gains, acting as a mature, cash-flowing blue-chip tech stock.
$86.7+247.2%

The 5-year machine cycle concludes.

  • Drivers: Doximity has successfully navigated the short-term debt cycle immune to rate shocks, and capitalized on the productivity boom via AI integration.
  • Frictions: Terminal multiple valuation is fully settled.
  • Net result: The asset rests at its true fundamental value, having closed the alpha gap completely and rewarded diamond hands.
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Here is the True Price path through the economic machine. Doximity is currently priced for a doomsday scenario that ignores its structural monopoly and pristine balance sheet. In our base case, the stock absorbs the near-term macro liquidity drain from the energy shock, but rapidly compounds as the $500M share buyback creates a hard price floor. By late 2026, the transition from cyclical pharma advertising to recurring AI workflow SaaS revenue will become visible in the earnings, forcing a massive multiple expansion. The net effect of our drivers (monopoly lock-in, buybacks, AI monetization) heavily outweighs the frictions (pharma ad freeze, AI compute costs).

  • Market digests the TrumpRx pharma freeze; ad budgets normalize by 2027.
  • The $500M share repurchase program aggressively reduces float at multi-year lows. - 300,000+ free AI users are successfully converted into paid enterprise hospital contracts.
  • Zero debt completely insulates the firm from the Warsh-era yield curve steepening.
  • The valuation multiple expands from a distressed 14x forward EPS back toward a premium SaaS multiple.
  • Net result is a ~230% cumulative gain over the 5-year horizon as the alpha gap closes.

2. Scenarios & Signals

2.1. Bull Case

What if the machine runs hot? If our base case plays out and key opportunities trigger, DOCS goes parabolic. The bull case requires the complete decoupling of DOCS's revenue from pharma marketing via hyper-adoption of its enterprise AI workflow suite.

  • AI Scribe adoption reaches 600,000+ paid seats, driving explosive ARR growth.
  • Margin expansion accelerates as compute costs for LLMs deflate rapidly.
  • A major tech incumbent (Microsoft, Oracle) attempts a hostile takeover or strategic buyout at a massive premium to capture the physician network.
  • Price compounds aggressively as the float shrinks and FOMO returns.

2.2. Bear Case

What breaks the machine? The bear case materializes if the cyclical headwinds prove to be structural terminal rot. If the TrumpRx regulations permanently ban or cap digital direct-to-physician marketing, the core revenue engine dies.

  • Pharma ad freeze becomes permanent legislation, destroying 80% of current revenue.
  • Epic Systems natively integrates free AI scribes, commoditizing DOCS's workflow tools.
  • Gross margins collapse under the weight of AI compute costs without matching revenue generation.
  • The stock becomes a value trap, stagnating as top-line growth permanently flatlines.

2.3. Behavioral Alpha Signals

Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.

Expected Volatility Regime

LowModerateHighExtreme

Greed and Fear Index

-100 Fear0+100 Greed
-80

Cycle Position

The reset is mostly complete and price drifts toward fair value.

EarlyAwareMomentumOvershootReversalCapit.StabilizeSTABILIZATION
Figure: Advisor position within the seven-stage market-recognition cycle. The highlighted point marks Stabilization.

What does Media Tell? (Crowd Consensus)

What is the noisy consensus pricing in? The crowd thinks Doximity is absolutely cooked, no cap. Wall Street sees the 4% revenue growth guidance and the TrumpRx pharma ad freeze and assumes the structural growth story is dead. They are pricing DOCS as a fading COVID-era pandemic darling that is getting rugged by AI capex taxes and defensive pharma budgets. The anchoring bias is trailing top-line growth: because ad revenues stalled, the crowd assumes the 80% physician monopoly is worthless. Total vibecession.

What Crowds Get Wrong? (Alpha/Value Gap)

Where is the variant perception? What is the crowd systematically ignoring? They are confusing a cyclical ad-budget freeze with a structural terminal decline. Doximity has zero debt, $700M+ in cash, and 55% EBITDA margins. It is totally immune to the Warsh rate shock. What happens when a debt-free monopoly with 90% gross margins trades at a distressed multiple? It aggressively buys back its own stock ($500M authorized). Furthermore, the market assigns zero value to their 300,000+ AI Scribe users. Converting this engagement into enterprise SaaS revenue will decouple DOCS from cyclical pharma ads. The alpha gap is massive.

When will Value Gap Repricing Happen? (Repricing Catalyst)

What closes this alpha gap? The catalyst arrives when DOCS formally commercializes its AI Scribe tool for enterprise health systems, proving to the street that it is transitioning from an ad-network to a sticky workflow SaaS. Expect this inflection around Q3 2026 (calendar late 2026). Signals will include rising Net Revenue Retention and a rebound in pharma bookings.

How is Asset Influenced by Macro Regime?

Does the macro machine support this? We are entering a Sound Money Warsh regime with higher-for-longer rates and steepening curves. Highly leveraged tech will get demolished. DOCS, with literally zero debt and massive free cash flow, has the ultimate macro tailwind. It is a duration-immunized tech asset. However, the Hormuz energy shock drains broad market liquidity, acting as a near-term headwind until sector rotation discovers DOCS's pristine balance sheet.

3. Positive & Negative Factors, Risks & Opportunities

3.1. Base-Case Forces

Near-certain positive forces

Top Drivers / Tailwinds

Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Drivers / Tailwinds with asset-specific estimated impacts and thesis rationale
Driver / TailwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
AI Workflow MonetizationInnovation And Product+120%Not quantifiedHow does an ad-network survive a marketing freeze? By becoming a mission-critical SaaS. DOCS has over 300,000 active prescribers testing its AI Scribe and workflow tools. When they flip the switch to monetize this engagement via enterprise health system contracts, it shifts the revenue mix from cyclical pharma ads to highly recurring software revenue. This is a structural upgrade to the economic machine, no cap. As the AI product matures over the next 5 years, it will drive massive ARR growth, commanding a premium multiple and driving the stock price aggressively higher.
Monopoly Network EffectCompetitive Positioning+80%Not quantifiedWhat is the most valuable asset in healthcare? Attention. With over 80 percent of US physicians actively using the platform, DOCS operates a literal monopoly on digital clinician networking. This network effect is virtually unassailable. Even during macro downturns or ad freezes, doctors continue to log in for telehealth, scheduling, and peer communication. This locked-in user base ensures that when pharma marketing budgets eventually unfreeze, the capital has nowhere else to go. This structural moat guarantees long-term pricing power and massive terminal value.
Massive Share BuybacksCapital Allocation+60%Not quantifiedWhat happens when a cash-printing machine gets priced for bankruptcy? Management apes in. Doximity authorized a 500 million dollar share repurchase program at cycle lows. For a company trading around a 3.5 billion dollar market cap, that retires roughly 14 percent of the float. This is financial engineering at its finest. By shrinking the denominator while the business stabilizes, EPS will artificially compound even if top-line growth is flat. Over the 5-year horizon, this aggressive capital return acts as a powerful mechanical driver for share price appreciation.
Pristine Balance SheetCapital Allocation+50%Not quantifiedAre we in a higher-for-longer rate regime? Yes. Does DOCS care? Absolutely not. This company has literally zero debt and over 700 million dollars in cash. While highly leveraged tech competitors get absolutely cooked by the Warsh shock and rising refinancing costs, Doximity is completely immunized against the short-term debt cycle. In fact, their cash hoard generates interest income. In a macro environment where liquidity is draining and capital costs are surging, a debt-free balance sheet is a massive structural premium that will attract institutional safe-haven flows.

Near-certain negative forces

Top Frictions / Headwinds

Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Frictions / Headwinds with asset-specific estimated impacts and thesis rationale
Friction / HeadwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Trumprx Pharma FreezeRegulatory-40%Not quantifiedWhat is the biggest drag on the machine right now? Government intervention. The TrumpRx initiative and aggressive drug pricing negotiations have forced pharmaceutical companies into a defensive crouch. When margins are threatened, marketing budgets are the first to get slashed. Because DOCS relies on pharma advertising for over 80 percent of its revenue, this regulatory shock directly throttles its core growth engine. Until the policy environment stabilizes, this will act as a persistent drag on top-line revenue, keeping a lid on explosive upside.
Warsh Shock Multiple CompressionMacroeconomic And Macrofinancial-35%Not quantifiedWhat happens when the Fed pivots to Sound Money? Yields rise, curves steepen, and long-duration tech valuations get crushed. Even though DOCS has no debt, its valuation is still tied to the broader software sector multiples. The Warsh shock shifts institutional capital away from growth equities and into banks, defense, and hard assets. This macro regime change acts as a structural friction, ensuring that DOCS will not easily reclaim its 2021 bubble-era valuation multiples, forcing the stock to rely purely on earnings growth rather than multiple expansion.
AI Capex TAXOperational Efficiency-25%Not quantifiedIs AI free? Absolutely not. Scaling DoxGPT and AI Scribe tools for hundreds of thousands of doctors requires massive cloud compute resources. This AI capex tax is already compressing Doximity's previously untouchable 93 percent gross margins down to 91 percent, and the cost curve is rising. If DOCS cannot monetize these AI users fast enough, the compute expenses will act as a structural margin drag, eating into free cash flow and disappointing Wall Street's profitability expectations over the forecast horizon.
BIG TECH EHR EncroachmentCompetitive Positioning-20%Not quantifiedWho else wants the AI healthcare workflow market? Everyone. Epic Systems, Microsoft, and Google are aggressively embedding native AI scribes and telehealth tools directly into the Electronic Health Record systems that hospitals already use. If these integrated tools are offered for free or bundled, Doximity's standalone workflow products face an existential threat. This competitive encroachment forces DOCS to constantly innovate just to maintain its user engagement, capping its pricing power and acting as a long-term structural friction.

3.2. Risks & Opportunities

Plausible downside scenarios

Tail Risks

Less likely downside scenarios that could materially hurt the outcome if they occur.

Scroll to view all columns

Tail risks with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Severe Pharma Marketing BAN20%-40%What if the regulatory freeze becomes a permanent ice age? If the TrumpRx initiative or subsequent populist legislation explicitly bans or severely restricts direct-to-physician digital marketing to lower drug costs, Doximity's primary revenue engine breaks permanently. The platform would be forced to rely entirely on its nascent software tools, which are currently sub-scale compared to the ad business. This would permanently cripple the company's cash flow and send the stock into a terminal death spiral.
Workflow Commoditization BY EHRS30%-30%What if AI scribes become a free commodity? If Epic Systems and Cerner roll out native, highly capable AI documentation tools embedded directly in the patient chart for free, doctors will have zero incentive to use Doximity's external workflow products. This would destroy Doximity's daily engagement loop. Without daily engagement, the value of the platform to pharma advertisers collapses. This competitive rug pull would break the core network effect and crush the stock's valuation.

Plausible upside scenarios

Tail Opportunities

Less likely upside scenarios that could materially improve the outcome if they occur.

Scroll to view all columns

Tail opportunities with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Strategic Acquisition Buyout25%+50%Who wouldn't want an 80 percent monopoly on US doctors? With zero debt, massive cash, and a depressed valuation, Doximity is a prime takeover target. A major tech incumbent like Microsoft or Oracle, or a massive private equity consortium, could launch a hostile takeover or strategic buyout. Acquiring DOCS instantly secures the ultimate healthcare data moat. A buyout would command a massive control premium, forcing an immediate and violent price spike to close the deal.
Enterprise SAAS Pivot Success35%+40%What if the ad network becomes a software empire? The bull trigger is Doximity successfully transitioning its massive free user base into paid, enterprise-wide SaaS contracts for hospital systems. If they can definitively prove that AI Scribe monetization is replacing cyclical pharma ad revenue, Wall Street will re-rate the stock from an ad-tech multiple to a premium vertical SaaS multiple. This structural pivot would decouple the company from marketing budget freezes and trigger explosive upside.

5. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 72,946Thinking Tokens: 11,627Response Tokens: 6,307Total Tokens: 90,880
Researcher modeExternal search used

External web search was used. The immutable publication retained the search terms, but no source URLs were recorded.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    inmemory_base_placeholders__latest_eod_close_price_with_stats__var2

  2. 02

    Global context in this run

    Used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Subject context

    Equity-specific subject and market context

  5. 05

    Global context

    Standard global market and cross-asset context

  6. 06

    Task framework

    Standard investment-forecast task guidelines

  7. 07
    Ray Dalio AI advisor icon

    Advisor framework

    Ray Dalio The Strategist Longterm

  8. 08

    Forecast output requested

    Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

03

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

File size
90.8K bytes
Words
12.8K words
Characters
90.8K characters

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From FileDateStatus
DeepSeek shock and AI economics reset2025-01-27OPEN ENDED TREND
US tariff regime escalation and trade-system rupture2025-02-01ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold2025-09-17ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal ReserveUS Bureau of Labor StatisticsUS Bureau of Economic AnalysisUS TreasuryUS Energy Information AdministrationReuters WorldAssociated Press World NewsBBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market Context through 2026-04-10

Download Archived Snapshot

Coverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10

File size
73.5K bytes
Words
9.8K words
Characters
73.5K characters

This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.

It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.

Top 3 market shifts from 2026 Year-to-Date Global Market Context through 2026-04-10
Top 3 Market Shifts From FileDateStatus
The Iran and Strait of Hormuz conflict shocked energy markets2026-02-28STARTED AND ONGOING
U.S. monetary policy entered the Warsh transition2026-01-30STARTED AND ACTIVE POLICY TRANSITION
Agentic AI and infrastructure spending kept expanding2026-01-01OPEN ENDED

Representative Sources of the Context File

Federal ReserveU.S. Bureau of Labor StatisticsU.S. Bureau of Economic AnalysisU.S. TreasuryU.S. Energy Information AdministrationReutersAssociated PressBBC News

And more sources from the retained context package.

02

Fundamental context

annual: 0 periods; quarterly: 0 periods

Currencies cited: USD (quote USD).

Search terms retained

  1. 1."Doximity" telehealth AI workflow margins
  2. 2."Doximity" "DOCS" revenue breakdown pharma marketing
  3. 3."Doximity" balance sheet debt cash flow 2024 2025

Search terms were retained, but this immutable publication does not contain source URLs for the run.

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.